The challenges of the diagnosis make it unclear whether the condition is outgrown or simply becomes better managed, experts say…There is no simple answer, said Thomas Power, director of the center for management of A.D.H.D. at Children’s Hospital of Philadelphia, and the senior author of the study. He was one of eight experts I consulted,…

Few differences were observed between individual pharmacotherapies for the treatment of adults with attention-deficit hyperactivity disorder (ADHD), according to the findings of a recently published systematic review and network meta-analysis.

In her presentation on psychopharmacology for primary care providers at the virtual 2020 American Academy of Pediatrics National Conference & Exhibition, Rebecca Baum, MD, pediatrician at Mission Children’s Hospital in Asheville, North Carolina, reminded practitioners of 3 guiding principles:

The U.S. Drug Enforcement Administration is making plans for a major expansion of its monitoring of prescriptions for opioids and other controlled substances, with the goal of identifying virtually every prescriber, pharmacy and patient in the country that shows signs of drug diversion or abusing their medication.

In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained the disappointment in the inability to leverage some of the emerging technologies being utilized in other spaces to detect ADHD early in patients.

Screening for attention deficit/hyperactivity disorder (ADHD) has not changed much over the years…While there are tools to help the psychiatry screen patients for the disorder, a high degree of suspicion remains the most important aspect of screening for ADHD.

There are a number of new treatments and therapies coming on board for attention deficit/hyperactivity disorder (ADHD). During the annual Neuroscience Education Institute Max! Virtual meeting, David Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, will present 5 different times about ADHD and some new insights into…

A team, led by Ann C. Childress, Center for Psychiatry and Behavioral Medicine, assessed the clinical efficacy, time to onset and duration of efficacy, and safety of PRC-063 compared to placebo in adult ADHD patients…PRC-063 is an extended-release formulation designed specifically to provide sustained delivery for patients with ADHD who require symptom control throughout the…

A team, led by Daniel J. Cox, University of Virginia Health Sciences Center, Department of Psychiatry and Neurobehavioral Sciences, investigated the non-inferiority of 2 long-acting psychostimulants on driving performance in young adults with ADHD…In the randomized, double-blind, cross-over procedure, each participant was dose-optimized on controlled-release methylphenidate PRC-063 (45, 70, or 100 mg/day) or lisdexamfetamine (30,…

Maternal use of valproic acid, but not lamotrigine, is associated with an increased risk for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) among children, according to a study published online Oct. 28 in Neurology.

A recent study found that children diagnosed with attention deficit/hyperactivity disorder (ADHD) had a 10-fold increase in the incidence of later development of bipolar disorder compared with matched children without ADHD.1 The comorbidity is common, has a more severe course than either diagnosis alone, and is associated with greater risk of suicide attempts.2

Several psychopharmacological and psychotherapeutic interventions can help treat adult ADHD, according to a presenter at the NEI Max virtual conference. “ADHD is predicated on childhood and adolescent presentation of ADHD symptoms, but there’s also the term called late-onset ADHD,” David W. Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School…